Shares of AveXis Inc (NASDAQ:AVXS) have earned a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $93.83.

A number of equities analysts have commented on AVXS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 target price on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. started coverage on shares of AveXis in a research note on Tuesday, May 23rd. They set a “buy” rating and a $90.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of AveXis in a research note on Friday, March 17th. Goldman Sachs Group, Inc. (The) lifted their target price on shares of AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, March 17th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $95.00 target price (up from $85.00) on shares of AveXis in a research note on Friday, March 17th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/20/avexis-inc-avxs-receives-average-recommendation-of-buy-from-analysts.html.

AveXis (AVXS) traded down 2.076% during mid-day trading on Tuesday, reaching $70.535. 330,673 shares of the company were exchanged. The company’s market capitalization is $1.96 billion. AveXis has a 1-year low of $31.55 and a 1-year high of $85.98. The company has a 50 day moving average of $74.27 and a 200-day moving average of $65.34.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.13. During the same period in the prior year, the firm earned ($1.24) EPS. On average, equities research analysts forecast that AveXis will post ($4.56) EPS for the current year.

In other news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $81.39, for a total value of $144,874.20. Following the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $144,874.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 5,341 shares of company stock worth $406,682 over the last three months.

Several large investors have recently added to or reduced their stakes in AVXS. Quantitative Systematic Strategies LLC bought a new stake in AveXis during the first quarter worth about $201,000. Candriam Luxembourg S.C.A. bought a new stake in AveXis during the first quarter worth about $1,901,000. FMR LLC increased its stake in AveXis by 67.6% in the fourth quarter. FMR LLC now owns 4,151,443 shares of the company’s stock worth $198,148,000 after buying an additional 1,674,424 shares during the period. Franklin Resources Inc. increased its stake in AveXis by 5.8% in the fourth quarter. Franklin Resources Inc. now owns 1,196,960 shares of the company’s stock worth $57,131,000 after buying an additional 65,550 shares during the period. Finally, Opus Point Partners Management LLC bought a new stake in AveXis during the fourth quarter worth about $239,000. 90.47% of the stock is currently owned by institutional investors and hedge funds.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.